AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.59+0.32 (+2.84%)
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Avalo Therapeutics has not reported a dividend
No dividend per share appears in Avalo Therapeutics's annual filings since fiscal 2012.